Israel - English - Ministry of Health

sanofi israel ltd - polystyrene sulphonate sodium - powder for suspension - polystyrene sulphonate sodium 99.934 % - polystyrene sulfonate - polystyrene sulfonate - treatment of hyperkalemia.

Kenya - English - Pharmacy and Poisons Board

la renon healthcare private limited la renon healthcare private limited - calcium polystyrene sulphonate bp - powder for oral suspension - calcium polystyrene sulphonate bp equivalent to… - polystyrene sulfonate

Kenya - English - Pharmacy and Poisons Board

calcium polystyrene sulphonate bp - powder for oral suspension - calcium polystyrene sulphonate bp equivalent to… - polystyrene sulfonate

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - calcium polystyrene sulphonate - powder for oral/rectal suspension - 99.934 percent weight/weight - drugs for treatment of hyperkalemia and hyperphosphatemia; polystyrene sulfonate

Canada - English - Health Canada

odan laboratories ltd - sodium polystyrene sulfonate - powder for suspension - 1g - sodium polystyrene sulfonate 1g - potassium-removing agents

Canada - English - Health Canada

odan laboratories ltd - sodium polystyrene sulfonate - suspension - 250mg - sodium polystyrene sulfonate 250mg - potassium-removing agents

Singapore - English - HSA (Health Sciences Authority)

medicell pharmaceutical (s) pte. ltd. - sodium polystyrene sulphonate - powder, for suspension - 94.3 mg/g - sodium polystyrene sulphonate 94.3 mg/g

Singapore - English - HSA (Health Sciences Authority)

medicell pharmaceutical (s) pte. ltd. - sodium polystyrene sulphonate - suspension - 15 g/60 ml - sodium polystyrene sulphonate 15 g/60 ml

United States - English - NLM (National Library of Medicine)

kvk-tech, inc. - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 1 g in 1 g - sodium polystyrene sulfonate is indicated for the treatment of hyperkalemia. limitation of use : sodium polystyrene sulfonate should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2)]. sodium polystyrene sulfonate is contraindicated in patients with the following conditions: • hypersensitivity to polystyrene sulfonate resins • obstructive bowel disease • neonates with reduced gut motility risk summary sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the practical exchange ratio of 1 meq potassium per 1 gram of resin. in neonates, sodium polystyrene sulfonate should not be given by the oral route. in both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with sodium polystyrene sulfonate use [see warnings and precautions (5.4)] .

United States - English - NLM (National Library of Medicine)

puracap laboratories, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 4.1 meq in 1 g - sodium polystyrene sulfonate powder, for suspension is indicated for the treatment of hyperkalemia. limitation of use: sodium polystyrene sulfonate powder, for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2)] . sodium polystyrene sulfonate powder, for suspension is contraindicated in patients with the following conditions: ● hypersensitivity to polystyrene sulfonate resins ● obstructive bowel disease ● neonates with reduced gut motility risk summary sodium polystyrene sulfonate powder, for suspension is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate powder, for suspension is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients,